LMB-100

DB18591InvestigationalProtein Based Therapies

LMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity.

Mechanism: Pharmacologically active on Mesothelin and Elongation factor 2
Curator reviewed
Also known as: Anti-mesothelin-pseudomonas exotoxin 24 cytolytic fusion protein lmb-100 · ANTI-MSLN-PE24 CFP LMB-100
Code names: LMB-100 · RG-7787 · RO-6927005

Resolves to

Compound

UNIID6AT024T4PCAS1841500-93-3

Targets

Q13421MSLNP13639EEF2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with LMB-100, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account